Anbio Biotechnology Class A Ordinary Shares (NNNN)
Anbio Biotechnology Class A Ordinary Shares operates in the Medical - Instruments & Supplies industry of the Healthcare sector, headquartered in Frankfurt am Main, HE, DE. The stock last traded at $9.89, down 4.44% on the session, giving a market capitalisation of $434.1M. On trailing twelve-month figures it carries a trailing P/E of 51.14, a net margin of 72.1%. Its beta of 5.35 implies it has historically moved more than the broad market.
Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.
Anbio Biotechnology Class A Ordinary Shares is most often compared with the following Healthcare names: